Baidu
map

PNAS:天然化合物角鲨胺有望用于帕金森病临床治疗

2017-01-20 佚名 生物谷

据科学家报道一种天然化合物能够通过阻断导致帕金森病的分子途径从而抑制毒性物质的产生。这些初步研究结果表明这种叫做角鲨胺的化合物有望得到多种途径开发用于治疗帕金森病。相关研究结果发表在国际学术期刊PNAS上。角鲨胺发现于20世纪90年代,是一种存在于角鲨科动物体内的类固醇物质。科学家通过合成更安全的类似物,曾将这种化合物用于癌症和眼部疾病的临床试验,目前一项针对帕金森病患者的临床试验正在计划


据科学家报道一种天然化合物能够通过阻断导致帕金森病的分子途径从而抑制毒性物质的产生。这些初步研究结果表明这种叫做角鲨胺的化合物有望得到多种途径开发用于治疗帕金森病。相关研究结果发表在国际学术期刊PNAS上。

角鲨胺发现于20世纪90年代,是一种存在于角鲨科动物体内的类固醇物质。科学家通过合成更安全的类似物,曾将这种化合物用于癌症和眼部疾病的临床试验,目前一项针对帕金森病患者的临床试验正在计划当中。

在这项新研究中,研究人员发现角鲨胺也能够显著抑制α-突触核蛋白形成毒性聚集体的过程,该过程被认为能够引发一系列分子事件最终导致帕金森病的发生。

研究人员在细胞和线虫模型上检测了角鲨胺的作用。在正常情况下,α-突触核蛋白能够帮助神经化学信号在神经元之间进行有效传递,但是当这种蛋白发生功能失调开始聚集成块就会形成毒性颗粒损伤脑细胞。研究人员发现角鲨胺能够通过竞争结合突触小泡上的α-突触核蛋白结合位点阻止这种蛋白的异常聚集,借助这种替换方式,角鲨胺可以显著降低毒性颗粒的形成速率。

研究人员还发现角鲨胺能够抑制这些毒性颗粒的毒性作用。

他们对线虫进行了基因改造在线虫的肌肉细胞内过表达α-突触核蛋白。随着线虫的发育,α-突触核蛋白形成的聚集体会导致线虫发生瘫痪,而角鲨胺能够阻止瘫痪的发生。

这些结果表明角鲨胺或可用于帕金森病的治疗,至少可以改善帕金森病的症状。不过还需要进一步的研究确定角鲨胺究竟能带来什么样的作用,目前也仍然不清楚角鲨胺能否到达帕金森病发生的主要脑部区域。研究人员计划在美国进行一项利用角鲨胺治疗帕金森病的临床试验。

原始出处

Michele Pernia,b, Céline Galvagniona,1, Alexander Maltsevc, Georg Meisla.et.al.A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity.PNAS.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1855951, encodeId=66ab185595123, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri May 12 09:45:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906332, encodeId=345f1906332c0, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Nov 09 23:45:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173629, encodeId=933b1e362974, content=有潜力的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170201/IMG589191708D5BD6502.jpg, createdBy=e9e22008791, createdName=Lidu20002000, createdTime=Wed Feb 01 15:38:14 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525804, encodeId=7c601525804e9, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Sun Jan 22 00:45:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538671, encodeId=08e515386e17d, content=<a href='/topic/show?id=59c044154e0' target=_blank style='color:#2F92EE;'>#天然化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44154, encryptionId=59c044154e0, topicName=天然化合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfa413003642, createdName=TZF0808, createdTime=Sun Jan 22 00:45:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171828, encodeId=42361e182802, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Jan 21 17:30:03 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
    2017-05-12 drwjr
  2. [GetPortalCommentsPageByObjectIdResponse(id=1855951, encodeId=66ab185595123, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri May 12 09:45:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906332, encodeId=345f1906332c0, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Nov 09 23:45:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173629, encodeId=933b1e362974, content=有潜力的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170201/IMG589191708D5BD6502.jpg, createdBy=e9e22008791, createdName=Lidu20002000, createdTime=Wed Feb 01 15:38:14 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525804, encodeId=7c601525804e9, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Sun Jan 22 00:45:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538671, encodeId=08e515386e17d, content=<a href='/topic/show?id=59c044154e0' target=_blank style='color:#2F92EE;'>#天然化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44154, encryptionId=59c044154e0, topicName=天然化合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfa413003642, createdName=TZF0808, createdTime=Sun Jan 22 00:45:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171828, encodeId=42361e182802, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Jan 21 17:30:03 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1855951, encodeId=66ab185595123, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri May 12 09:45:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906332, encodeId=345f1906332c0, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Nov 09 23:45:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173629, encodeId=933b1e362974, content=有潜力的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170201/IMG589191708D5BD6502.jpg, createdBy=e9e22008791, createdName=Lidu20002000, createdTime=Wed Feb 01 15:38:14 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525804, encodeId=7c601525804e9, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Sun Jan 22 00:45:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538671, encodeId=08e515386e17d, content=<a href='/topic/show?id=59c044154e0' target=_blank style='color:#2F92EE;'>#天然化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44154, encryptionId=59c044154e0, topicName=天然化合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfa413003642, createdName=TZF0808, createdTime=Sun Jan 22 00:45:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171828, encodeId=42361e182802, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Jan 21 17:30:03 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
    2017-02-01 Lidu20002000

    有潜力的药物

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1855951, encodeId=66ab185595123, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri May 12 09:45:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906332, encodeId=345f1906332c0, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Nov 09 23:45:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173629, encodeId=933b1e362974, content=有潜力的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170201/IMG589191708D5BD6502.jpg, createdBy=e9e22008791, createdName=Lidu20002000, createdTime=Wed Feb 01 15:38:14 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525804, encodeId=7c601525804e9, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Sun Jan 22 00:45:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538671, encodeId=08e515386e17d, content=<a href='/topic/show?id=59c044154e0' target=_blank style='color:#2F92EE;'>#天然化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44154, encryptionId=59c044154e0, topicName=天然化合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfa413003642, createdName=TZF0808, createdTime=Sun Jan 22 00:45:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171828, encodeId=42361e182802, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Jan 21 17:30:03 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1855951, encodeId=66ab185595123, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri May 12 09:45:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906332, encodeId=345f1906332c0, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Nov 09 23:45:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173629, encodeId=933b1e362974, content=有潜力的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170201/IMG589191708D5BD6502.jpg, createdBy=e9e22008791, createdName=Lidu20002000, createdTime=Wed Feb 01 15:38:14 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525804, encodeId=7c601525804e9, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Sun Jan 22 00:45:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538671, encodeId=08e515386e17d, content=<a href='/topic/show?id=59c044154e0' target=_blank style='color:#2F92EE;'>#天然化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44154, encryptionId=59c044154e0, topicName=天然化合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfa413003642, createdName=TZF0808, createdTime=Sun Jan 22 00:45:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171828, encodeId=42361e182802, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Jan 21 17:30:03 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1855951, encodeId=66ab185595123, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri May 12 09:45:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906332, encodeId=345f1906332c0, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Nov 09 23:45:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173629, encodeId=933b1e362974, content=有潜力的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170201/IMG589191708D5BD6502.jpg, createdBy=e9e22008791, createdName=Lidu20002000, createdTime=Wed Feb 01 15:38:14 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525804, encodeId=7c601525804e9, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Sun Jan 22 00:45:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538671, encodeId=08e515386e17d, content=<a href='/topic/show?id=59c044154e0' target=_blank style='color:#2F92EE;'>#天然化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44154, encryptionId=59c044154e0, topicName=天然化合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfa413003642, createdName=TZF0808, createdTime=Sun Jan 22 00:45:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171828, encodeId=42361e182802, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Jan 21 17:30:03 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
    2017-01-21 杨柳青青

    签到学习了…………

    0

相关资讯

对于帕金森病非运动症状的建议

直立性低血压作为帕金森病的非运动症状之一,直立性低血压的存在可能增加多系统萎缩的风险。 指南建议:1.避免暴饮暴食、饮酒、夜间喝咖啡、暴露在温暖环境中、容量不足和使用已知的导致直立性低血压的药物;2.如果出现症状性直立性低血压时可增加盐的摄入(每餐1 g);3.抬高床头(30°~40°);4.穿弹力袜、腹带;5.增加锻炼、少食多餐;6.药物治疗可以选择米多君或者氟氢可的松(可能有效但有副作用)。逼

SCI TRANSL MED:帕金森病患者的福音-吸入型左旋多巴

这些结果支持进一步发展CVT-301,以期更好地用于PD的治疗。

帕金森病抑郁、焦虑及精神病性障碍的诊断标准及治疗指南(一)

帕金森病(Parkinson’s disease)是常见的中枢神经系统变性疾病,主要临床表现为震颤、少动、强直、姿势平衡障碍等运动症状。除运动功能障碍外,不同程度的抑郁、焦虑及精神病性障碍等非运动症状也比较常见,对患者的生活质量、日常功能及预后造成影响,近年来逐渐备受关注。有报道帕金森病患者抑郁障碍的发生率为40%-50%,焦虑障碍的发生率为3.6%-40.0%,抑郁与焦虑障碍经常共存,并可在

光刺激特定脑区改善帕金森病患者的时间感知及认知障碍

上周,小编曾报道过Science期刊上一项关于“时间观念”的研究——中脑多巴胺调控着动物的时间判断能力。这篇文章表明,黑质多巴胺活性的强弱影响着动物对时间间隔长短的估计。我们知道,黑质多巴胺神经元缺失的帕金森病人往往出现时间感知障碍。12月15日,发表于Current Biology上的研究表明,帕金森病患者所出现的认知问题可能正是由于这种时间观念的缺失。并且,研究人员通过光遗传学技术刺激特定脑区

帕金森病步态障碍临床特点及研究进展

本文原载于《中华神经医学杂志》2016年第4期帕金森病(Parkinson's disease)是一种中老年人常见的神经系统退行性疾病,其病理改变主要表现为选择性中脑黑质多巴胺能神经元的进行性变性死亡,残余神经元内路易小体形成,进而引起纹状体多巴胺含量显著减少。帕金森病的临床表现主要为运动迟缓、静止性震颤、肌强直和姿势步态障碍[1]。其中步态障碍是帕金森病运动功能缺损的常见表现,更是导致帕金森

Baidu
map
Baidu
map
Baidu
map